120 related articles for article (PubMed ID: 30790732)
1. Correlation of Ki-67 Index with Volumetric Segmentation and its Value as a Prognostic Marker in Glioblastoma.
Henker C; Kriesen T; Schneider B; Glass Ä; Scherer M; Langner S; Erbersdobler A; Piek J
World Neurosurg; 2019 May; 125():e1093-e1103. PubMed ID: 30790732
[TBL] [Abstract][Full Text] [Related]
2. Is Ki-67 index overexpression in IDH wild type glioblastoma a predictor of shorter Progression Free survival? A clinical and Molecular analytic investigation.
Armocida D; Frati A; Salvati M; Santoro A; Pesce A
Clin Neurol Neurosurg; 2020 Nov; 198():106126. PubMed ID: 32861131
[TBL] [Abstract][Full Text] [Related]
3. Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma.
Tsidulko AY; Kazanskaya GM; Kostromskaya DV; Aidagulova SV; Kiselev RS; Volkov AM; Kobozev VV; Gaitan AS; Krivoshapkin AL; Grigorieva EV
Tumour Biol; 2017 Sep; 39(9):1010428317724282. PubMed ID: 28945172
[TBL] [Abstract][Full Text] [Related]
4. The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma.
Liu X; Mangla R; Tian W; Qiu X; Li D; Walter KA; Ekholm S; Johnson MD
J Neurooncol; 2017 Dec; 135(3):553-560. PubMed ID: 28889246
[TBL] [Abstract][Full Text] [Related]
5. Ki-67 Proliferative Activity in the Tumor Margins as a Robust Prognosis Factor in Glioblastoma Patients.
Tejada S; Becerra-Castro MV; Nuñez-Cordoba J; Díez-Valle R
J Neurol Surg A Cent Eur Neurosurg; 2021 Jan; 82(1):53-58. PubMed ID: 33260244
[TBL] [Abstract][Full Text] [Related]
6. Ki-67 antigen expression as a prognostic factor in primary and recurrent astrocytomas.
Eneström S; Vavruch L; Frånlund B; Nordenskjöld B
Neurochirurgie; 1998 Mar; 44(1):25-30. PubMed ID: 9757314
[TBL] [Abstract][Full Text] [Related]
7. Perfusion Parameter Obtained on 3-Tesla Magnetic Resonance Imaging and the Ki-67 Labeling Index Predict the Overall Survival of Glioblastoma.
Fudaba H; Momii Y; Matsuta H; Onishi K; Kawasaki Y; Sugita K; Shimomura T; Fujiki M
World Neurosurg; 2021 May; 149():e469-e480. PubMed ID: 33567368
[TBL] [Abstract][Full Text] [Related]
8. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
[TBL] [Abstract][Full Text] [Related]
9. Different assessments of immunohistochemically stained Ki-67 and hTERT in glioblastoma multiforme yield variable results: a study with reference to survival prognosis.
Persson A; Englund E
Clin Neuropathol; 2008; 27(4):224-33. PubMed ID: 18666438
[TBL] [Abstract][Full Text] [Related]
10. Volumetric quantification of glioblastoma: experiences with different measurement techniques and impact on survival.
Henker C; Kriesen T; Glass Ä; Schneider B; Piek J
J Neurooncol; 2017 Nov; 135(2):391-402. PubMed ID: 28755324
[TBL] [Abstract][Full Text] [Related]
11. Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma.
Petrik V; Saadoun S; Loosemore A; Hobbs J; Opstad KS; Sheldon J; Tarelli E; Howe FA; Bell BA; Papadopoulos MC
Clin Chem; 2008 Apr; 54(4):713-22. PubMed ID: 18281421
[TBL] [Abstract][Full Text] [Related]
12. Ki-67 labeling index in glioblastoma; does it really matter?
Alkhaibary A; Alassiri AH; AlSufiani F; Alharbi MA
Hematol Oncol Stem Cell Ther; 2019 Jun; 12(2):82-88. PubMed ID: 30552865
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
Hoster E; Rosenwald A; Berger F; Bernd HW; Hartmann S; Loddenkemper C; Barth TF; Brousse N; Pileri S; Rymkiewicz G; Kodet R; Stilgenbauer S; Forstpointner R; Thieblemont C; Hallek M; Coiffier B; Vehling-Kaiser U; Bouabdallah R; Kanz L; Pfreundschuh M; Schmidt C; Ribrag V; Hiddemann W; Unterhalt M; Kluin-Nelemans JC; Hermine O; Dreyling MH; Klapper W
J Clin Oncol; 2016 Apr; 34(12):1386-94. PubMed ID: 26926679
[TBL] [Abstract][Full Text] [Related]
14. Fractional Anisotropy Correlates with Overall Survival in Glioblastoma.
Huber T; Bette S; Wiestler B; Gempt J; Gerhardt J; Delbridge C; Barz M; Meyer B; Zimmer C; Kirschke JS
World Neurosurg; 2016 Nov; 95():525-534.e1. PubMed ID: 27565465
[TBL] [Abstract][Full Text] [Related]
15. Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma.
Seidel C; Dörner N; Osswald M; Wick A; Platten M; Bendszus M; Wick W
BMC Cancer; 2011 Apr; 11():127. PubMed ID: 21481277
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas.
Wakimoto H; Aoyagi M; Nakayama T; Nagashima G; Yamamoto S; Tamaki M; Hirakawa K
Cancer; 1996 Jan; 77(2):373-80. PubMed ID: 8625247
[TBL] [Abstract][Full Text] [Related]
17. Volumetric assessment of glioblastoma and its predictive value for survival.
Henker C; Hiepel MC; Kriesen T; Scherer M; Glass Ä; Herold-Mende C; Bendszus M; Langner S; Weber MA; Schneider B; Unterberg A; Piek J
Acta Neurochir (Wien); 2019 Aug; 161(8):1723-1732. PubMed ID: 31254065
[TBL] [Abstract][Full Text] [Related]
18. Morphological MRI-based features provide pretreatment survival prediction in glioblastoma.
Pérez-Beteta J; Molina-García D; Martínez-González A; Henares-Molina A; Amo-Salas M; Luque B; Arregui E; Calvo M; Borrás JM; Martino J; Velásquez C; Meléndez-Asensio B; de Lope ÁR; Moreno R; Barcia JA; Asenjo B; Benavides M; Herruzo I; Lara PC; Cabrera R; Albillo D; Navarro M; Pérez-Romasanta LA; Revert A; Arana E; Pérez-García VM
Eur Radiol; 2019 Apr; 29(4):1968-1977. PubMed ID: 30324390
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients.
Chiba Y; Hashimoto N; Tsuboi A; Rabo C; Oka Y; Kinoshita M; Kagawa N; Oji Y; Sugiyama H; Yoshimine T
Brain Tumor Pathol; 2010 Apr; 27(1):29-34. PubMed ID: 20425045
[TBL] [Abstract][Full Text] [Related]
20. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
